Solving Complex Brain Tumor Mysteries: A Neuropathologist's Motivation

Jump To Section

• Complex Brain Tumor Cases as Motivation
• Molecular Classification Challenges in Neuropathology
• Innovative Cost Solutions for Brain Tumor Diagnosis
• Alzheimer's and Neurodegeneration Research
• Mentoring Future Physician-Scientists
• Academic Medical Center Advantages
• Full Transcript

Complex Brain Tumor Cases as Motivation

Dr. Sebastian Brandner, MD, finds daily motivation in the 5% of challenging brain tumor cases that defy easy diagnosis at his academic medical center. "What drives us is the curiosity - how can we solve that medical problem?" explains the neuropathology professor. Unlike routine cases, these complex presentations require innovative diagnostic approaches and keep clinical work intellectually stimulating.

Molecular Classification Challenges in Neuropathology

While molecular classification revolutionized brain tumor diagnosis, Dr. Sebastian Brandner, MD, notes it created new diagnostic dilemmas. "We now find combinations of brain tumor markers that don't fit established patterns," he tells Dr. Anton Titov, MD. These edge cases motivate his team to develop additional tests that reveal deeper biological insights about tumor behavior and potential treatment targets.

Innovative Cost Solutions for Brain Tumor Diagnosis

Dr. Brandner addresses NHS financial pressures through scalable solutions like a brain tumor diagnostic startup initially funded by The Brain Tumor Charity. "By attracting more referrals, we develop economies of scale that lower costs while maintaining excellence," he explains. This model reduced testing expenses significantly while expanding access to advanced molecular diagnostics for patients across the healthcare system.

Alzheimer's and Neurodegeneration Research

Beyond brain tumors, Dr. Brandner's team investigates critical neurodegeneration questions, including potential iatrogenic Alzheimer's transmission. "We're examining whether medical procedures could transmit pathogenic proteins," he states. This research builds on their recent publications and could reshape understanding of neurodegenerative disease prevention.

Mentoring Future Physician-Scientists

Developing young talent represents another key motivation for Dr. Brandner. "Seeing trainees grow into clinically excellent academics is tremendously rewarding," he tells Dr. Anton Titov, MD. His department promotes promising researchers into lecturer positions, creating a pipeline for the next generation of neuropathology experts.

Academic Medical Center Advantages

Dr. Sebastian Brandner, MD, emphasizes how his center's collaborative environment enables breakthroughs. "Without our multidisciplinary teams and research infrastructure, none of this would be possible," he explains. This academic hospital setting combines complex case referrals, cutting-edge technology, and translational research opportunities that drive innovation in neuropathology and neurology.

Full Transcript

Dr. Anton Titov, MD: Professor Sebastian Brandner, we have a great discussion of brain diseases. We discussed how brain tumors benefit from the science of neuropathology and neurology. But it's interesting to know this. What drives you in life? What makes you tick? What makes you determined and successful in your research and clinical work?

Dr. Sebastian Brandner, MD: First of all, it's a very interesting job that we're having here. It's a major academic health science center and a major referral hospital with lots of specialists working around us. I have to say it becomes interesting because we are embedded in one of these centers of excellence for brain research.

Dr. Sebastian Brandner, MD: We do neurodegeneration research and brain tumor research. Without a proper functioning of these associated and affiliated departments, all the success would be impossible. There's no point coming every day to work and having to deal with only small numbers of clinical cases. It’s boring to deal with only small quantities and repetitive diagnoses.

Dr. Sebastian Brandner, MD: What we want to see is interesting diseases and patients that fascinate us every day. We have 5% of our work being new every day—problematic clinical cases and unsolvable cases. That drives us. The curiosity motivates us.

Dr. Sebastian Brandner, MD: How can we solve that medical problem? There is the molecular classification of brain tumors. We saw a lot of problems with the diagnosis, but now we realize we created a few more new problems. These problems are at the fringes of these clear-cut diagnoses. Now we find new combinations of brain tumor markers that don't seem to make sense. Brain tumor markers sometimes don't fit into the diagnostic landscape. So that drives us.

Dr. Sebastian Brandner, MD: What's behind that brain tumor problem? That's why we use additional diagnostic tests to find out more about a brain tumor.

Dr. Sebastian Brandner, MD: Other things that drive me, in particular, is leading the department. We have financial challenges at the NHS. At our hospital, we have to make savings, but we have to be clever about how to make them. We can make savings by attracting more referrals of brain tumor patients. This gives us the opportunity to develop economies of scale.

Dr. Sebastian Brandner, MD: It's an important factor that allows us to invest and cut down the prices. This is great for the NHS, very useful for patients, and charities like that. The Brain Tumor Charity funded a startup with £75,000 eight or nine years ago to set up this molecular diagnostics test. The aim was to make sure revenue from the new brain tumor diagnostic test covers the expenditures for staff and equipment.

Dr. Sebastian Brandner, MD: So this is now very economical. This is the sort of thing that drives me. Every year, twice a year, I will be summoned to my clinical director. He says, "Where are the savings? Can you demonstrate you can cut down costs 10% here and there?" This can be challenging. I think a hospital director shouldn't be too much focused on savings because you have to keep the center of excellence running.

Dr. Sebastian Brandner, MD: But these are the challenges that keep me awake at night. The third challenge is getting research grants to continue brain tumor research. We must ask the questions that I really am interested in. We must find new brain tumor biomarkers.

Dr. Sebastian Brandner, MD: How can we find the brain tumor marker that is predictive of a certain brain tumor survival? We must do neurodegeneration research. We have to find answers to the question that our recent publication has opened now. Is there another way of transmitting protein diseases? Are certain Alzheimer’s patients at risk? Is it a medical procedure that can transmit Alzheimer’s disease? Which other medical procedures can transmit Alzheimer’s disease? How can we actually find a way of discovering Alzheimer’s disease transmission?

Dr. Sebastian Brandner, MD: All these questions keep us awake at night. These are the constellations that make me want to come here. I want to achieve something. I’d like to have a great team of colleagues around. We have trainees who deliver a great deal of work and fantastic brain tumor research results. I'm happy to promote trainees into lecturer positions.

Dr. Sebastian Brandner, MD: I see young physicians growing up, trainees becoming clinically excellent academics. This is the environment where this is possible.

Dr. Anton Titov, MD: What I'm hearing is that it is part of the challenge. Your interest is to be a medical detective on behalf of the patients. You investigate what it is that is not discovered, what it is that's not on the surface, what seems to be a large challenge. That is a part of your being a medical detective.

Dr. Sebastian Brandner, MD: Yes!

Dr. Anton Titov, MD: Professor Sebastian Brandner, thank you very much for this conversation on brain tumors and larger aspects of neurology. I really appreciate it. I am sure it will be very interesting for viewers around the world. Thank you for the interview!

Dr. Sebastian Brandner, MD: Thanks for coming here!